For Australian private health insurers
Prevent repeat GI hospital claims.
GI is a major hospital benefits category. Nerva uses AI to deliver evidence-based GI care at population scale, targeting the persistent symptoms and repeat care behind that spend.
- Australian-founded
- Developed with Monash
- Published active-control RCT¹
- Live with HIF⁷
The member problem
Persistent GI symptoms affect far more than the gut.
GI care is designed to investigate structural disease. When symptoms persist, members are often left without a scalable care pathway. Functional GI conditions such as IBS disrupt daily life and drive repeat care.
- 1 in 5Australians are affected by IBS.12
- 3 in 4say symptoms disrupt daily life.13
- 68%report moderate-to-extreme hopelessness.13
The solution
Functional GI care, delivered through software.
Funds already offer heart, joint, weight and mental-health programs. Nerva fills the functional GI gap with a clinician-designed six-week software program.10
- Multimodal functional GI care
Expand access beyond specialist capacity
Daily guided sessions combine gut-brain care, diet and GI education, breathing and symptom tracking, without appointments or waitlists.
- AI-guided engagement
Keep more members engaged through completion
AI tailors pre-authored education to member preferences and selected focus areas; therapy, triage and the protocol remain clinician-governed.
- Outcomes and reporting
Measure the outcomes behind your spend
Validated symptom measures give funds clear reporting on completion and clinical response.
- Clinical governance
Scale safely without adding clinical headcount
Automated delivery scales access, with screening, warning signs and escalation governed by Nerva’s medical director.
Independent evaluation by PHTI
“Within the evidence reviewed, Nerva presented the strongest overall evidence for improving IBS symptoms.”
Peterson Health Technology Institute (PHTI)Virtual Gastrointestinal Care Solutions, March 20265
81%1of participants met the primary symptom endpoint (≥50-point IBS-SSS improvement), vs 63% on active control.
Randomised controlled trial · N=244 · active control · AJG 2025 Read the research →
- Clinically significant abdominal-pain reduction, vs 35% on control1
- 71%
- Nerva's core brain-gut behavioural technique showed efficacy similar to the low-FODMAP diet in a Monash randomised trial4
- Similar efficacy
Enrollment and engagement
The functional GI benefit members actually use.
Nerva combines trusted clinician referrals, instant access and a consumer experience that keeps members participating.
- 8,000
- active US providers
- 300K+
- people supported
- 156M
- gut-brain care minutes
Nerva platform data, August 2026.
The claims opportunity
Find the persistent-symptom cohort in your claims.
Digestive-system hospital spend is large. Repeat care and paid benefits show where to start.
The category, in fund-paid benefits
$1.69bn
in fund-paid digestive-system hospital benefits in 2024–25.2
- for 536,000+ scope-related hospital separations.2
- $786m
- variation in repeat colonoscopy across local areas.3
- 18-fold
The pilot cohort
One claims code will not find them.
Find members where symptom signals, repeat care and paid benefits overlap.
01
Diagnosis and symptom signals
IBS and other DGBIs, abdominal pain, bloating, altered bowel habit.
02
Longitudinal care pattern
Repeated investigation and recurrent same-day GI care across 24 to 36 months.
03
Fund economics
Scopes, related hospital episodes and the benefits your fund actually paid.
The intersection
Members who appear across all three layers form the pilot cohort.
Claims identify the opportunity. A pilot measures symptoms, engagement and downstream hospital use.
Partnership spotlight
Live in Australia, with HIF.
Eligible HIF members have accessed Nerva through their fund since March 2025, with activation and outcomes reporting built in.
- 300,000+ people have used Nerva worldwide8
- 8,000 active US providers8
- Monash research collaboration, Australian participants1,4
Program facts as at August 2026.7 Activation and outcome figures are shared with funds under discussion.
Find the right funding pathway for your fund.
The care stays the same. Together, we choose how members access it.
CDMP
A dietitian-led plan with consent, six weeks of Nerva and outcomes returned for review.11
Extras
A gut health or health-management benefit that removes the member price barrier.
Fund-sponsored program
Eligibility, activation and outcomes reporting built around your fund.
We can test the best fit with your clinical, product and legal teams.
See how Nerva could work for your health fund.
Review the member experience, measurement approach and path to a claims-based pilot.
References
- Anderson, Ellen J.; Peters, Simone L.; Gibson, Peter R.; Halmos, Emma P. Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome. The American Journal of Gastroenterology 120(2):p 440-448, February 2025. DOI: 10.14309/ajg.0000000000002921
- Department of Health and Aged Care, Hospital Casemix Protocol Annual Report 2024–25: privately insured digestive-system separations and fund-paid hospital and in-hospital medical benefits, Australian private-day and private-other rows, AR-DRG version 11.0 only. Suppressed small cells omitted, so totals are lower bounds.
- Australian Commission on Safety and Quality in Health Care, Atlas Focus Report: Colonoscopy: repeat colonoscopy within three years varies 18-fold across local areas; some early repeat procedures are clinically necessary. The variation supports investigation, not a presumption of waste.
- Peters, S. L.; Yao, C. K.; Philpott, H.; Yelland, G. W.; Muir, J. G.; Gibson, P. R. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 2016;44(5):447–459.
- Peterson Health Technology Institute. Virtual Gastrointestinal Care Solutions Assessment. March 2026.
- Mindset Health participation in the CMS ACCESS Model, 2026: outcomes-based arrangements in the musculoskeletal and behavioural health tracks in US Original Medicare. Cited here as outcomes-measurement and reconciliation infrastructure; it is not evidence of Australian coverage or savings.
- HIF and Mindset Health member health program partnership, current as at August 2026. Program details, activation and outcomes figures are available to funds under discussion.
- Internal Nerva platform figures, August 2026.
- APRA, Quarterly private health insurance statistics, March 2026: 12.79 million Australians held hospital cover and funds paid AUD 4.75 billion in hospital benefits in the quarter. The per-covered-life figure divides FY2024–25 HCP digestive-system benefits by March-2026-quarter membership, so it is approximate and period-mismatched by construction.
- Lacy, B. E. et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. The American Journal of Gastroenterology, 2021: gut-directed psychotherapies, including gut-directed hypnotherapy, are recommended options for IBS.
- Private Health Insurance (Health Insurance Business) Rules (Cth), legislation.gov.au F2018L00718: the elements of a chronic disease management program, including a written plan, patient consent, specified services and coordination by a suitable person. How a fund classifies and offers any program is that fund's own product and governance decision.
- Healthdirect Australia. Irritable bowel syndrome: IBS affects around one in five people in Australia.
- Nerva by Mindset Health. State of IBS 2025 Report: cross-sectional survey of 3,403 respondents across Australia, the US, UK and Europe.
Nerva complements existing clinical care and does not replace a gastroenterologist, dietitian or psychologist. Program availability through a fund depends on that fund's own rules, product governance and clinical review.